Neuland Laboratories provides contract research, manufacturing, and API services. It has two FDA-approved manufacturing facilities in India with over 40,000 square feet of state-of-the-art R&D space. Neuland has over 1000 employees, focuses on markets in the EU, US and Japan, and generates over $70 million in annual sales. It has experience developing and manufacturing a wide range of drug compounds and certifications from global regulatory bodies.
The document outlines the manufacturing plan and costing for a diagnostic kit called SaphvidTM that detects pre-eclampsia. It details the product development process including validation of raw materials, assembly, clinical trials, and manufacturing. The total estimated cost of product development is £460,000. The manufacturing process is described along with equipment qualification, process validation, and control of critical steps. Clinical trials involving over 1,000 subjects are planned in the UK. The document provides timelines, costs, and supplier information for pilot and full-scale manufacturing of SaphvidTM.
Suspend Polyzone is an innovative residual spray that combines the active ingredient deltamethrin with a proprietary polymer suspension. This formulation exhibits extended residual control of up to 90 days, protecting the active ingredient from weather and abrasion through a controlled-release polymer layer. The polymer layer shields the active ingredient, keeping it securely in place on treated surfaces where it can effectively control pests over an extended period. This new technology increases customer satisfaction through reduced call-backs and improves pest management by providing flexibility in reapplication intervals.
Gosselin is a leading European manufacturer of disposable plastics products for laboratory use, located in northern France. Since 1965, it has specialized in injection molding, blow molding, and other plastic manufacturing techniques. The company has grown significantly over the past 40+ years and now employs 300 people across multiple facilities with a focus on quality and clean production standards. Gosselin supplies a wide range of labware products globally and continues innovating through research and development.
This presentation summarizes regulations for medical devices in Korea, the United States, and Europe. It discusses classification systems, submission types and requirements. Current topics in US regulation like 510k reform, the medical device tax, FDA-CMS collaboration, and initiatives to promote innovation are also covered. The presentation concludes that while regulations differ somewhat globally, collaboration can help support global trials and submissions, and regulations are evolving to balance innovation and healthcare costs.
G7 Pre-eclampsia Diagnostic device - Development and IP costPriyesh Waghmare
This document provides details on the product development plan and quality management systems of G7 Diagnostics, including:
- A Gantt chart outlining the 1-year timeline for product development, manufacturing, quality control, legal registration, and salaries
- Plans to register for ISO 13485 and attain CE marking to enable sales in Europe
- Specifications for the diagnostic strip, meter, and quality control processes
- Intellectual property status and registration for patents
- Internal management policies focused on quality, safety, and regulations
The summary conveys the key activities and goals of G7 Diagnostics' product development and regulatory compliance efforts.
Dr Reddys Cps Presentation Linked In Aug 2011Christian_Jones
Dr. Reddy's Laboratories provides affordable and innovative medicines through pharmaceutical services, active ingredients, and generics. It has 14,000+ employees across 16 manufacturing sites. The company has a strong pipeline of over 200 projects in development across APIs, finished dosages, biosimilars, and specialty products. It aims to leverage its science, technology, and customer service to provide affordable medicines through organic growth and strategic acquisitions. Its custom pharmaceutical services division provides end-to-end capabilities from discovery to commercial launch for a broad base of large pharma, mid-sized pharma, and emerging biotech clients.
CTC Union is a telecommunications company established in 1993 with headquarters in Taiwan. It has capital of USD $8.1 million and certifications in ISO9001:2000, FCC, CE, and RoHS. The company focuses on research and development, investing 27% of its organization in R&D. It operates a factory for manufacturing telecommunications equipment and has global sales channels and customers around the world. CTC Union is dedicated to providing professional optical fiber solutions and connecting the world as it builds for the future.
Medix's mission is to provide high quality health products and services that exceed customer expectations in areas like obesity, gastroenterology, and the central nervous system. Its vision is to achieve $100 million in sales by 2012 through sustained growth. Core values include effectiveness, quality, creativity, loyalty, passion, commitment, integration, and process efficiency. Medix has over 475 employees and 50 years of experience in Mexico. It offers a portfolio of products for gastroenterology and other medical areas. Medix is developing its business through partnerships, a customer relationship management system, exports, and a future pharmaceutical research center.
The document outlines the manufacturing plan and costing for a diagnostic kit called SaphvidTM that detects pre-eclampsia. It details the product development process including validation of raw materials, assembly, clinical trials, and manufacturing. The total estimated cost of product development is £460,000. The manufacturing process is described along with equipment qualification, process validation, and control of critical steps. Clinical trials involving over 1,000 subjects are planned in the UK. The document provides timelines, costs, and supplier information for pilot and full-scale manufacturing of SaphvidTM.
Suspend Polyzone is an innovative residual spray that combines the active ingredient deltamethrin with a proprietary polymer suspension. This formulation exhibits extended residual control of up to 90 days, protecting the active ingredient from weather and abrasion through a controlled-release polymer layer. The polymer layer shields the active ingredient, keeping it securely in place on treated surfaces where it can effectively control pests over an extended period. This new technology increases customer satisfaction through reduced call-backs and improves pest management by providing flexibility in reapplication intervals.
Gosselin is a leading European manufacturer of disposable plastics products for laboratory use, located in northern France. Since 1965, it has specialized in injection molding, blow molding, and other plastic manufacturing techniques. The company has grown significantly over the past 40+ years and now employs 300 people across multiple facilities with a focus on quality and clean production standards. Gosselin supplies a wide range of labware products globally and continues innovating through research and development.
This presentation summarizes regulations for medical devices in Korea, the United States, and Europe. It discusses classification systems, submission types and requirements. Current topics in US regulation like 510k reform, the medical device tax, FDA-CMS collaboration, and initiatives to promote innovation are also covered. The presentation concludes that while regulations differ somewhat globally, collaboration can help support global trials and submissions, and regulations are evolving to balance innovation and healthcare costs.
G7 Pre-eclampsia Diagnostic device - Development and IP costPriyesh Waghmare
This document provides details on the product development plan and quality management systems of G7 Diagnostics, including:
- A Gantt chart outlining the 1-year timeline for product development, manufacturing, quality control, legal registration, and salaries
- Plans to register for ISO 13485 and attain CE marking to enable sales in Europe
- Specifications for the diagnostic strip, meter, and quality control processes
- Intellectual property status and registration for patents
- Internal management policies focused on quality, safety, and regulations
The summary conveys the key activities and goals of G7 Diagnostics' product development and regulatory compliance efforts.
Dr Reddys Cps Presentation Linked In Aug 2011Christian_Jones
Dr. Reddy's Laboratories provides affordable and innovative medicines through pharmaceutical services, active ingredients, and generics. It has 14,000+ employees across 16 manufacturing sites. The company has a strong pipeline of over 200 projects in development across APIs, finished dosages, biosimilars, and specialty products. It aims to leverage its science, technology, and customer service to provide affordable medicines through organic growth and strategic acquisitions. Its custom pharmaceutical services division provides end-to-end capabilities from discovery to commercial launch for a broad base of large pharma, mid-sized pharma, and emerging biotech clients.
CTC Union is a telecommunications company established in 1993 with headquarters in Taiwan. It has capital of USD $8.1 million and certifications in ISO9001:2000, FCC, CE, and RoHS. The company focuses on research and development, investing 27% of its organization in R&D. It operates a factory for manufacturing telecommunications equipment and has global sales channels and customers around the world. CTC Union is dedicated to providing professional optical fiber solutions and connecting the world as it builds for the future.
Medix's mission is to provide high quality health products and services that exceed customer expectations in areas like obesity, gastroenterology, and the central nervous system. Its vision is to achieve $100 million in sales by 2012 through sustained growth. Core values include effectiveness, quality, creativity, loyalty, passion, commitment, integration, and process efficiency. Medix has over 475 employees and 50 years of experience in Mexico. It offers a portfolio of products for gastroenterology and other medical areas. Medix is developing its business through partnerships, a customer relationship management system, exports, and a future pharmaceutical research center.
Petrobras is a technology-based organization that invests heavily in research and development (R&D). In 2006, Petrobras spent $583 million on R&D, with 48% allocated to exploration and production. One of Petrobras' technological programs, called PROGER, focuses on renewable energy like biofuels. PROGER has 66 biofuel projects exploring biodiesel, bioethanol, and synthetic fuels. Petrobras has successfully tested biodiesel production from castor oil using both single-step and two-step processes and is building commercial production facilities. It is also researching non-food bioethanol and hydrogenation of vegetable oils to produce diesel fuel.
Marcus evans 9th annual commercial translation of regenerative medicine fun...ProteusVenturePartners
This document discusses funding and commercialization strategies for regenerative medicine companies. It notes that while regenerative medicine has made great progress, serious commercialization challenges remain, including developing optimal cells for therapy, manufacturing at scale, addressing regulatory and IP issues, and determining business models. New economic realities require a more capital efficient development model as the "valley of death" between research and commercialization expands. Regenerative medicine translation centers may help enable more efficient technology development and collaborations to address these challenges.
Norner Innovation AS is an industrial innovation company with over 30 years of experience in polyolefin development. It has expertise in plastics processing, additives, polymers, and advanced laboratories. Norner works with over 300 customers in 15 countries on projects related to product development, technical support, and applied research. It has over 60 staff with expertise in various areas of plastics and materials. Norner helps customers with industrial developments, applications testing, special technologies, and acts as a qualification partner for additives and materials.
We are into manufacturing of bulk Drug Intermediates and Active Pharmaceutical Ingredients (API). Our core competence is to satisfy our clients who are looking for manufacturers committed to quality and delivery with focus on cost reduction of products. We have recently developed many intermediates and APIs in-house to cater to existing and new customers. Our commitment to quality and customer delight has been a key strength contributing to our growth and success.
This document outlines a presentation on clinical research and development challenges and opportunities. It discusses the low productivity and increasing costs of R&D, potential loss of revenue from expiring patents, and reasons for low productivity such as target and trial design issues. It also covers trends like globalization of clinical trials to reduce costs and access large patient populations. Finally, it discusses the need for quality and qualified investigators to address the supply and demand imbalance.
■ Hair Bang: 3 Types of Wave Length (650,660,630nm) / LLLT(Low Level Laser Therapy)
■ Hair Boom: 1 Type of Wave (660nm) / LLLT / CE,KFDA Certificates
■ Total 69 light (Hair Bang: 27 LD, 42 LED / Hair Boom: all 69 LD)
■ Laser mode / Vibration Mode
■ CE, KFDA, CFDA Certificates. FDA in progress.
Hair Bang(A.K.A Hair Boom) is a laser helmet for alopecia, hair loss treatment using LLLT technology which is approved by U.S FDA. Basically laser therapy is not dangerous and has no side effects compared to other treatment such as hair transplant, medication and so on. Hair Boom and Hair Bang product recovers scalp skin and capillary by using LLLT( Low Level Laser Therapy) stimulating blood flow circulation in head. Finally, this function deliveries oxygen and nutrients from activated capillary vessel to hair and eventually makes hair regrow and improves hair loss condition.
Visit us at: wtlaser.com
This document discusses the challenges of innovation in technology development. It notes that while new tools exist to drive innovation, commercializing new technologies faces increasing barriers due to industry consolidation, profitability challenges, and producers' reluctance to take risks as the first to adopt new technologies. Partnerships between technology developers and users are important to overcoming these barriers to innovation.
Sami Direct
World's Largest Ayurveda Company
> 74 Patents
> ISO 22000
> 120+ Scientist
> International Quality Products
> Recipient of many National & International Awards
> Business in all 7 continents
A Presentation on Sami Direct Opportunity.
Please visit to understand the opportunity.
Kindly call on +91-9225232100 in case you need further assistant.
The document discusses tools and frameworks for developing regional innovation hubs. It provides an overview of Hubconcepts' 20 years of experience analyzing over 200 science and technology parks. The Hubconcepts Innovation Hub Framework is presented as a tool to identify, analyze, and plan innovation hubs using "visual ecosystem profiles". Case studies of Otaniemi, Finland and other regions are analyzed to demonstrate how the framework can support the development of innovation hubs and activities. Hubconcepts offers services to support profiling and managing next-generation innovation hubs.
The document discusses tools and frameworks for developing regional innovation hubs. It provides an overview of Hubconcepts' 20 years of experience analyzing over 200 science and technology parks. The Hubconcepts Innovation Hub Framework is presented as a tool to identify, analyze, and plan innovation hubs using "visual ecosystem profiles". Case studies of Otaniemi, Finland and other regions are analyzed to demonstrate how the framework can support the development of innovation hubs and activities. Hubconcepts offers services to support profiling and managing next-generation innovation hubs.
This is a presentation about Profile of Sami Direct and Its Nutraceutical Range.
If you like the presentation or the products, You can contact on +919225232100 for further details.
Corporate Presentation Ll Focus Ls Mar 2012 V1Murali Apparaju
Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry.
This is the corporate presentation of Yara International.
Yara delivers solutions for sustainable agriculture and the environment. Our fertilizers and crop nutrition programs help produce the food required for the growing world population. Our industrial products and solutions reduce emissions, improve air quality and support safe and efficient operations. Founded in Norway in 1905, Yara has a worldwide presence with sales to 150 countries. Safety is always our top priority.
www.yara.com
Elias Zerhouni - January 22, BioForward Breakfast Event PresentationBioForward
This document summarizes a leadership breakfast talk given by Elias Zerhouni on challenges facing the biopharmaceutical industry. It notes a significant drop in productivity as evidenced by increasing clinical development times and decreasing FDA approvals. Major drivers of this change include evolving patient needs, increased regulation, changing payer landscapes, and issues with the existing models of innovation and large company organization. It argues that a new approach is needed focusing on translational medicine, open innovation, priority disease areas, and leveraging local innovative ecosystems.
This document summarizes the key points of a proposal for a food irradiation facility. It discusses how irradiation can eliminate disease-causing germs from foods while maintaining nutritional value. The summary includes the proposed machinery and costs, staffing plan and wages, other expenses, break-even analysis, financial viability, estimated turnover and profits. The proposal requests a total investment of 4.3 crore rupees, and estimates annual profits of 63.75% on investment and 42.28% on sales.
Maja Wessels, EVP of Public Affairs for First Solar, presented at the GW Solar Institute Symposium on April 19, 2010. More information at solar.gwu.edu/Symposium.html
The document discusses the growth and development of the biotechnology industry in India from 2003-2012. It outlines the establishment of ABLE (Association of Biotech Led Enterprises) in 2003 as the nodal organization for the biotech industry in India, which has grown to over 220 members across various biotech sectors. It then discusses the key sectors within the Indian biotech industry including biopharma, bioservices, bioagri, bioindustrial and bioinformatics, highlighting major players and market trends within each sector such as growth in vaccines, biosimilars, medical devices, and contract research outsourcing.
More Related Content
Similar to Neuland Contract Manufacturing Services
Petrobras is a technology-based organization that invests heavily in research and development (R&D). In 2006, Petrobras spent $583 million on R&D, with 48% allocated to exploration and production. One of Petrobras' technological programs, called PROGER, focuses on renewable energy like biofuels. PROGER has 66 biofuel projects exploring biodiesel, bioethanol, and synthetic fuels. Petrobras has successfully tested biodiesel production from castor oil using both single-step and two-step processes and is building commercial production facilities. It is also researching non-food bioethanol and hydrogenation of vegetable oils to produce diesel fuel.
Marcus evans 9th annual commercial translation of regenerative medicine fun...ProteusVenturePartners
This document discusses funding and commercialization strategies for regenerative medicine companies. It notes that while regenerative medicine has made great progress, serious commercialization challenges remain, including developing optimal cells for therapy, manufacturing at scale, addressing regulatory and IP issues, and determining business models. New economic realities require a more capital efficient development model as the "valley of death" between research and commercialization expands. Regenerative medicine translation centers may help enable more efficient technology development and collaborations to address these challenges.
Norner Innovation AS is an industrial innovation company with over 30 years of experience in polyolefin development. It has expertise in plastics processing, additives, polymers, and advanced laboratories. Norner works with over 300 customers in 15 countries on projects related to product development, technical support, and applied research. It has over 60 staff with expertise in various areas of plastics and materials. Norner helps customers with industrial developments, applications testing, special technologies, and acts as a qualification partner for additives and materials.
We are into manufacturing of bulk Drug Intermediates and Active Pharmaceutical Ingredients (API). Our core competence is to satisfy our clients who are looking for manufacturers committed to quality and delivery with focus on cost reduction of products. We have recently developed many intermediates and APIs in-house to cater to existing and new customers. Our commitment to quality and customer delight has been a key strength contributing to our growth and success.
This document outlines a presentation on clinical research and development challenges and opportunities. It discusses the low productivity and increasing costs of R&D, potential loss of revenue from expiring patents, and reasons for low productivity such as target and trial design issues. It also covers trends like globalization of clinical trials to reduce costs and access large patient populations. Finally, it discusses the need for quality and qualified investigators to address the supply and demand imbalance.
■ Hair Bang: 3 Types of Wave Length (650,660,630nm) / LLLT(Low Level Laser Therapy)
■ Hair Boom: 1 Type of Wave (660nm) / LLLT / CE,KFDA Certificates
■ Total 69 light (Hair Bang: 27 LD, 42 LED / Hair Boom: all 69 LD)
■ Laser mode / Vibration Mode
■ CE, KFDA, CFDA Certificates. FDA in progress.
Hair Bang(A.K.A Hair Boom) is a laser helmet for alopecia, hair loss treatment using LLLT technology which is approved by U.S FDA. Basically laser therapy is not dangerous and has no side effects compared to other treatment such as hair transplant, medication and so on. Hair Boom and Hair Bang product recovers scalp skin and capillary by using LLLT( Low Level Laser Therapy) stimulating blood flow circulation in head. Finally, this function deliveries oxygen and nutrients from activated capillary vessel to hair and eventually makes hair regrow and improves hair loss condition.
Visit us at: wtlaser.com
This document discusses the challenges of innovation in technology development. It notes that while new tools exist to drive innovation, commercializing new technologies faces increasing barriers due to industry consolidation, profitability challenges, and producers' reluctance to take risks as the first to adopt new technologies. Partnerships between technology developers and users are important to overcoming these barriers to innovation.
Sami Direct
World's Largest Ayurveda Company
> 74 Patents
> ISO 22000
> 120+ Scientist
> International Quality Products
> Recipient of many National & International Awards
> Business in all 7 continents
A Presentation on Sami Direct Opportunity.
Please visit to understand the opportunity.
Kindly call on +91-9225232100 in case you need further assistant.
The document discusses tools and frameworks for developing regional innovation hubs. It provides an overview of Hubconcepts' 20 years of experience analyzing over 200 science and technology parks. The Hubconcepts Innovation Hub Framework is presented as a tool to identify, analyze, and plan innovation hubs using "visual ecosystem profiles". Case studies of Otaniemi, Finland and other regions are analyzed to demonstrate how the framework can support the development of innovation hubs and activities. Hubconcepts offers services to support profiling and managing next-generation innovation hubs.
The document discusses tools and frameworks for developing regional innovation hubs. It provides an overview of Hubconcepts' 20 years of experience analyzing over 200 science and technology parks. The Hubconcepts Innovation Hub Framework is presented as a tool to identify, analyze, and plan innovation hubs using "visual ecosystem profiles". Case studies of Otaniemi, Finland and other regions are analyzed to demonstrate how the framework can support the development of innovation hubs and activities. Hubconcepts offers services to support profiling and managing next-generation innovation hubs.
This is a presentation about Profile of Sami Direct and Its Nutraceutical Range.
If you like the presentation or the products, You can contact on +919225232100 for further details.
Corporate Presentation Ll Focus Ls Mar 2012 V1Murali Apparaju
Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry.
This is the corporate presentation of Yara International.
Yara delivers solutions for sustainable agriculture and the environment. Our fertilizers and crop nutrition programs help produce the food required for the growing world population. Our industrial products and solutions reduce emissions, improve air quality and support safe and efficient operations. Founded in Norway in 1905, Yara has a worldwide presence with sales to 150 countries. Safety is always our top priority.
www.yara.com
Elias Zerhouni - January 22, BioForward Breakfast Event PresentationBioForward
This document summarizes a leadership breakfast talk given by Elias Zerhouni on challenges facing the biopharmaceutical industry. It notes a significant drop in productivity as evidenced by increasing clinical development times and decreasing FDA approvals. Major drivers of this change include evolving patient needs, increased regulation, changing payer landscapes, and issues with the existing models of innovation and large company organization. It argues that a new approach is needed focusing on translational medicine, open innovation, priority disease areas, and leveraging local innovative ecosystems.
This document summarizes the key points of a proposal for a food irradiation facility. It discusses how irradiation can eliminate disease-causing germs from foods while maintaining nutritional value. The summary includes the proposed machinery and costs, staffing plan and wages, other expenses, break-even analysis, financial viability, estimated turnover and profits. The proposal requests a total investment of 4.3 crore rupees, and estimates annual profits of 63.75% on investment and 42.28% on sales.
Maja Wessels, EVP of Public Affairs for First Solar, presented at the GW Solar Institute Symposium on April 19, 2010. More information at solar.gwu.edu/Symposium.html
The document discusses the growth and development of the biotechnology industry in India from 2003-2012. It outlines the establishment of ABLE (Association of Biotech Led Enterprises) in 2003 as the nodal organization for the biotech industry in India, which has grown to over 220 members across various biotech sectors. It then discusses the key sectors within the Indian biotech industry including biopharma, bioservices, bioagri, bioindustrial and bioinformatics, highlighting major players and market trends within each sector such as growth in vaccines, biosimilars, medical devices, and contract research outsourcing.
Similar to Neuland Contract Manufacturing Services (20)
1. 1 of 23 1 of 35
Neuland Laboratories- Contract
Research/ Manufacturing Services
September 13, 2010
Confidential
Information
2. 2 of 23
Key Differentiators
Integrated facilities to provide all chemistry related services
Focused on EU, NA and Japanese markets
No conflict with customer with a service provider model
Operations geared to provide customers with high degree of
reliability
3. 3 of 23
Neuland Overview
Focused on contract research, manufacturing and APIs
2 US FDA approved manufacturing facilities
40,000 sq. ft. state-of-the-art R&D facility in Hyderabad,
Over 1000 employees, over 180 in R&D
Scaled-up over 300 processes from lab to plant
Over 400 DMFs filed worldwide
Sales revenues of over $70 MM, over 80% into US & EU
Public listed company on the BSE and NSE
4. 4 of 23
The Distinguished Board Includes…
Dr. Chris Cimarusti Shashi Budhiraja Dr. D. R. Rao Dr. Will Mitchell Daya Chandrahas
former Senior VP of former advisor to the Organic Chemist, former Associate Dean Nominee director of
Pharmaceutical UN Secretary General Chairman and of Fuqua School of EXIM Bank of India
development at BMS Promoter of Neuland Business, Duke
University
Humayun Dhanrajgir Sucheth Davuluri GVK Rama Rao P.V. Maiya Saharsh Davuluri
former Vice Chairman CEO of Neuland promoter director and founding Chairman of head of Contract
and Managing practicing advocate the ICICI Bank Research and new
Director of Glaxo business initiatives of
(India) Neuland
5. 5 of 23
Our Growth Story
1986 1994 1997 2004 2007 2007 2008
First Neuland’s First FDA US office Japan office JV with CATO Receives
Milestones product: PMDA
IPO approval opened opened Research Inc
Albuterol approval
Sulfate
90.0 1000.0
80.0
70.0 800.0
Sales ($ in mn)
Volume (tonnes)
60.0
600.0
50.0
40.0
400.0
30.0
20.0 200.0
10.0
0.0 0.0
Year
6. 6 of 23
Facilities Certification
Certification Date Unit I* Unit II
US FDA Mar 2008
EDQM Dec 2005
PMDA (Japan) Jan 2009
TGA (Australia) May 2004
German Health Authority Feb 2007
ISO 14000:2004 Nov 2007
OHSAS 18001:1999 Nov 2007
ISO 27001 Apr 2008
ISO 9001:2000 Jan 2005
* Location of R&D Center
7. 7 of 23
Neuland’s Services in Chemistry and Manufacturing
Click here for classes of compounds
Click here for list of chemical reactions
8. 8 of 23
Chemistry Capabilities
Class of compounds Scale of operations
Amino Acids (synthetic) Lab, Kilo & Production
Heterocyclics Lab, Pilot & Production
Macrolides/Ketolides Lab, Kilo scale
Nucleosides Lab, Kilo scale
Oncology (Cytotoxic) compounds Lab, Kilo scale
Peptides and building blocks Lab, Pilot & Production
Prostaglandins Lab, Kilo scale
Quinolones Lab, Pilot & Production
Steroids Lab, Pilot & Production
Vitamin D2 analogues Lab, Kilo scale
9. 9 of 23
Development and Manufacturing Infrastructure
Development Scale-up Manufacture
11 development labs 3 kilo labs 2 manufacturing
55 fume hoods GMP pilot plant with sites
mg to gm scale two production areas 11 diverse
0.5-50 kg batch size production blocks
Analytical R&D
kg to tonne scale
Neuland performs active capacity management
to ensure future scalability and 30% buffer
10. 10 of 23
Analytical Infrastructure
Dedicated AR&D facility in the R&D center to support all activities
from discovery to development
300 MHz FT NMR (Bruker)
LC-MS-MS (Waters)
GC-MS (Perkin Elmer)
XRD (PANalytical)
HPLC with UV/PDA/ RI detectors (Waters)
FT-IR (Perkin Elmer)
UV visible spectrophotometer (Perkin Elmer)
Preparatory HPLC (Waters)
Particle Size Analyzer (Malvern)
DSC (Perkin Elmer)
Digital polarimeter
TGA (Perkin Elmer)
11. 11 of 23
Thank You!
For more information please Neuland Laboratories Limited
contact: 204, Meridian Plaza
Ameerpet, Hyderabad – 500 016
• Saradhi Bolli Andhra Pradesh, India
Manager Business Development
Tel : +91 40 3021 1661
Email: saradhi@neulandlabs.com
Fax : +91 40 2341 2957
Phone: +91-99660-30784 Website: www.neulandlabs.com